GILD Gilead Sciences Inc

Price (delayed)

$71.33

Market cap

$89.43B

P/E Ratio

17.31

Dividend/share

$2.81

EPS

$4.12

Enterprise value

$114.72B

Gilead Sciences, Inc. /ˈɡɪliəd/, is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the ...

Highlights
GILD's P/E is 92% below its last 4 quarters average of 230.6 and 73% below its 5-year quarterly average of 64.3
GILD's gross profit is up by 23% YoY and by 3.6% QoQ
The quick ratio has contracted by 50% YoY but it has grown by 6% from the previous quarter
Gilead Sciences's debt has increased by 25% YoY

Key stats

What are the main financial stats of GILD
Market
Shares outstanding
1.25B
Market cap
$89.43B
Enterprise value
$114.72B
Valuations
Price to earnings (P/E)
17.31
Price to book (P/B)
4.54
Price to sales (P/S)
3.36
EV/EBIT
14.78
EV/EBITDA
12.03
EV/Sales
4.31
Earnings
Revenue
$26.64B
EBIT
$7.76B
EBITDA
$9.54B
Free cash flow
$8.47B
Per share
EPS
$4.12
Free cash flow per share
$6.75
Book value per share
$15.71
Revenue per share
$21.23
TBVPS
$20.17
Balance sheet
Total assets
$67.98B
Total liabilities
$48.27B
Debt
$30.18B
Equity
$19.7B
Working capital
$3.71B
Liquidity
Debt to equity
1.53
Current ratio
1.36
Quick ratio
1.05
Net debt/EBITDA
2.65
Margins
EBITDA margin
35.8%
Gross margin
80.1%
Net margin
19.4%
Operating margin
36.7%
Efficiency
Return on assets
7.8%
Return on equity
27.8%
Return on invested capital
17.9%
Return on capital employed
13.4%
Return on sales
29.1%
Dividend
Dividend yield
3.94%
DPS
$2.81
Payout ratio
68.2%

GILD stock price

How has the Gilead Sciences stock price performed over time
Intraday
-0.6%
1 week
1.02%
1 month
-0.53%
1 year
8.65%
YTD
22.43%
QTD
3.59%

Financial performance

How have Gilead Sciences's revenue and profit performed over time
Revenue
$26.64B
Gross profit
$21.35B
Operating income
$9.79B
Net income
$5.16B
Gross margin
80.1%
Net margin
19.4%
The operating income has surged by 115% since the previous quarter
The operating margin has soared by 106% from the previous quarter
GILD's gross profit is up by 23% YoY and by 3.6% QoQ
GILD's revenue is up by 20% year-on-year and by 4.2% since the previous quarter

Growth

What is Gilead Sciences's growth rate over time

Valuation

What is Gilead Sciences stock price valuation
P/E
17.31
P/B
4.54
P/S
3.36
EV/EBIT
14.78
EV/EBITDA
12.03
EV/Sales
4.31
GILD's P/E is 92% below its last 4 quarters average of 230.6 and 73% below its 5-year quarterly average of 64.3
Gilead Sciences's equity has increased by 9% YoY and by 4% from the previous quarter
The stock's price to book (P/B) is 6% more than its last 4 quarters average of 4.3 and 3.2% more than its 5-year quarterly average of 4.4
GILD's revenue is up by 20% year-on-year and by 4.2% since the previous quarter
GILD's price to sales (P/S) is 7% less than its 5-year quarterly average of 3.6 but 5% more than its last 4 quarters average of 3.2

Efficiency

How efficient is Gilead Sciences business performance
Gilead Sciences's ROIC has soared by 171% from the previous quarter
GILD's return on sales has surged by 151% since the previous quarter

Dividends

What is GILD's dividend history
DPS
$2.81
Dividend yield
3.94%
Payout ratio
68.2%
Recent dividends

Financial health

How did Gilead Sciences financials performed over time
GILD's total assets is 41% higher than its total liabilities
The quick ratio has contracted by 50% YoY but it has grown by 6% from the previous quarter
Gilead Sciences's current ratio has decreased by 42% YoY
Gilead Sciences's debt is 53% higher than its equity
Gilead Sciences's debt has increased by 25% YoY
The company's debt to equity rose by 14% YoY but it fell by 3.8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.